References
- What are the key statistics about acute lymphocytic leukemia? Atlanta, GA: American Cancer Society; 2017 Jan 5 [cited 2017 Dec 8]. Available from: https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/key-statistics.html
- Acute lymphoblastic leukemia. Rye Brook, NY: Leukemia & Lymphoma Society; 2017 [cited 2017 Dec 8]. Available from: https://www.lls.org/leukemia/acute-lymphoblastic-leukemia
- Typical treatment of acute lymphocytic leukemia. Atlanta, GA: American Cancer Society; 2017 Aug 18 [8 Dec 2017]. Available from: https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/typical-treatment.html
- Noone AM, Howlader N, Krapcho M, et al., editors. Seer cancer statistics review, 1975–2015. Bethesda, MD: National Cancer Institute, 1975–2015.
- Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580. Epub 2017/07/13. doi: 10.1001/jamaoncol.2017.0580
- Brown PA, Shah B, Fathi A, et al. Nccn guidelines insights: acute lymphoblastic leukemia, version 1.2017. J Nat Compr Cancer Network: JNCCN. 2017;15:1091–102. doi: 10.6004/jnccn.2017.0147
- Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–1531. Epub 2018/01/24. doi: 10.1182/blood-2017-08-798322
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. Epub 2018/02/01. doi: 10.1056/NEJMoa1709866
- Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v69–v82. Epub 2016/04/07.
- Sutton R, Shaw PJ, Venn NC, et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015;168:395–404. Epub 2014/10/14. doi: 10.1111/bjh.13142
- Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–76. Epub 2012/03/24. doi: 10.1182/blood-2011-09-377713
- Zhou Y, Slack R, Jorgensen JL, et al. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. clinical lymphoma. Myeloma Leukemia. 2014;14:319–26. doi: 10.1016/j.clml.2014.01.002
- Eckert C, Hagedorn N, Sramkova L, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29(8):1648–1655. doi: 10.1038/leu.2015.59
- Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from children’s oncology group study AALL0232. Blood. 2015;126:964–71. doi: 10.1182/blood-2015-03-633685
- Conter V, Valsecchi MG, Parasole R, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123(10):1470–1478. doi: 10.1182/blood-2013-10-532598
- Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129:347–57. Epub 2016/12/03. doi: 10.1182/blood-2016-07-726307
- Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant.. 2016;51:786–92. Epub 2016/02/22. doi: 10.1038/bmt.2016.20